Recently Featured

Moderna flu vaccine wins unanimous support from FDA panel

June 24, 2026
The FDA advisory panel has unanimously endorsed Moderna’s flu vaccine, a significant development for the company following the FDA’s earlier decision to decline a review of the vaccine earlier this year. This endorsement positions Moderna to potentially transform its standing in the competitive landscape of influenza vaccines, which has become increasingly critical in light of…

Eli Lilly Ends 340B Drug Discounts for Non-Compliant Hospitals

June 24, 2026
Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program after failing to receive comprehensive claims data. This decision marks a significant shift in Lilly’s approach to the 340B program, which is designed to provide discounted medications to safety-net…

Patent Certifications and Suitability Petitions Impacting Generic Drug Availability

June 24, 2026
Recent developments in patent certifications and suitability petitions present significant implications for the availability of generic drugs in the pharmaceutical market. The U.S. Food and Drug Administration (FDA) has outlined specific guidelines that govern how these petitions are filed and processed, which directly affects the timeline for generic drug entry into the marketplace. As patent…

Impact of Early Life Adversity on Epigenome at Molecular Level Mapped in Macaques

June 24, 2026
Research led by Arizona State University and Vanderbilt University has mapped the lasting effects of early life adversity (ELA) on the epigenome of free-living rhesus macaques, revealing significant implications for understanding health across the lifespan. By integrating detailed life histories with genomic data from 12 adult tissues, the study provides compelling molecular evidence that ELA…

Ongoing Cases